Reprogramming Hepatic Resilience: BMK1 as a Cytoprotective Axis in Liver Ischemia-reperfusion Injury

Liver transplantation remains the treatment of choice for end-stage liver disease.1 Advances in machine perfusion preservation technologies have expanded graft utilization and improved access to transplantation.2 Nevertheless, ischemia-reperfusion injury (IRI) continues to represent a major challenge in transplantation, contributing to early graft dysfunction, delayed recovery, and long-term complications.3 Despite decades of investigation, therapeutic strategies focused primarily on sterile inflammation have yielded only modest clinical benefit. Increasing attention has therefore shifted toward intracellular stress-response pathways that determine whether hepatocytes adapt to injury or undergo irreversible damage. In this context, the study by Liu et al4 provides mechanistic evidence supporting big mitogen-activated protein kinase 1 (BMK1/ERK5) as a candidate regulator of hepatocellular survival during transplant-associated IRI. More broadly, BMK1 represents part of a stress-adaptation signaling network increasingly recognized as a key determinant of graft resilience. A major strength of this work relies on the integration of human transplant data with experimental modeling. In a cohort of 60 liver transplant recipients, increased intrahepatic BMK1 expression was associated with preserved histology and improved graft function. Recipients demonstrating increased posttransplant BMK1 exhibited lower postoperative alanine aminotransferase levels and faster biochemical recovery, suggesting a role for BMK1 in hepatocellular resistance to ischemic stress. The authors appropriately acknowledge that correlations between BMK1 expression and postoperative day 1 alanine aminotransferase lacked robustness across analyses, indicating that the clinical association should be interpreted cautiously. Such modest correlations are expected in transplantation, where donor characteristics, preservation variables, and recipient factors interact to influence outcomes. Despite prior observations in other organ systems,5 the findings provide biologically plausible support for mechanistic exploration. In liver, BMK1 appear to act as a mechanosensitive mitogen-activated protein kinase (MAPK) activated by oxidative stress, inflammatory cytokines, and reperfusion-associated shear stress through upstream kinases such as mitogen-activated protein kinase kinase 2,3,5 and integrin-Sarcoma pathways. It functions in endothelial cells, hepatocytes, vascular smooth muscle cells, and immune cells to integrate metabolic and inflammatory signals.5 Upstream of BMK1 activation in the liver, multiple injury types and flow responsive signaling pathways converge on the mitogen-activated protein kinase kinase 2,3,5 kinase cascade, including integrin-focal adhesion kinase-sarcoma mechanotransduction triggered by extracellular matrix stiffness and reperfusion-associated oxidative stress, receptor tyrosine kinase signaling (eg, vascular endothelial growth factor receptor, epidermal growth factor receptor, platelet-derived growth factor receptor), inflammatory stimuli such as tumor necrosis factor-alpha, interleukin-1 beta, and lipopolysaccharide, and metabolic stress sensors including AMP-activated protein kinase and mitochondrial reactive oxygen species. Downstream, BMK1 regulates transcriptional survival and regenerative programs via myocyte enhancer factor 2-Krüppel-like factor (KLF) signaling and crosstalk with Hippo-Yes-associated protein (YAP) pathways, promoting endothelial integrity, hepatocyte survival, angiogenesis, metabolic adaptation, and coordinated tissue repair after ischemic stress.5,6 A schematic overview of these upstream activators and downstream biological programs is provided in Figure 1.FIGURE 1.: BMK1 signaling as a cytoprotective stress-response axis in liver IRI. IRI-associated stressors, including oxidative stress, inflammatory cytokines, and reperfusion-induced shear stress, activate upstream MEKK2/3-MEK5 signaling cascades leading to activation of BMK1/ERK5 across multiple hepatic cell populations, including hepatocytes, endothelial cells, vascular smooth muscle cells, and immune cells. BMK1 integrates metabolic and inflammatory injury signals and promotes adaptive transcriptional survival programs through MEF2-KLF4 signaling, while modulating Hippo pathway activity via YAP activation. These coordinated stress-response mechanisms enhance hepatocyte survival, endothelial protection and angiogenesis, and metabolic resilience and tissue repair. Collectively, activation of BMK1-dependent pathways contributes to improved graft recovery and functional resilience following liver transplantation. BMK1, big mitogen-activated protein kinase 1; IRI, ischemia-reperfusion injury; KLF4, Krüppel-like factor 4; MEF2, myocyte enhancer factor 2; MEKK2/3-MEK5, mitogen-activated protein kinase kinase 2,3,5; ROS, reactive oxygen species; YAP, Yes-associated protein.Using murine warm ischemia models, the investigators demonstrated rapid induction of BMK1 following ischemia, peaking within hours of reperfusion alongside upregulation of downstream transcriptional mediators such as KLF4. Functional experiments further reveal that pharmacological or genetic inhibition of BMK1 markedly exacerbates liver injury, resulting in higher transaminase levels, worsened histological damage, and increased necroinflammation, consistent with prior reports.5 Conversely, BMK1 overexpression confers hepatoprotection, positioning this kinase as a key signaling node governing cellular adaptation to oxidative stress. These findings align with an evolving conceptual framework in transplantation biology in which graft injury is determined not only by immune activation but also by intrinsic cellular fitness and stress-adaptation capacity.6 A particularly novel aspect of the study is the identification of a BMK1-dependent transcriptional program involving YAP and KLF4. BMK1 overexpression increases YAP abundance and promotes its dephosphorylation, while YAP silencing abolishes BMK1-mediated cytoprotection. These data support a mechanistic model whereby BMK1 may modulate YAP activity through ITCH-mediated ubiquitination of the large tumor suppressor kinase 1, relieving inhibitory Hippo signaling and enabling nuclear YAP translocation. This posttranscriptional regulation links MAPK signaling to Hippo pathway control and has important implications for regenerative biology. The cooperation between YAP and KLF4 further strengthens the mechanistic interpretation of the data. Silencing either transcription factor disrupts nuclear localization of the other and suppresses downstream gene expression, ultimately increasing susceptibility to hypoxia-reoxygenation injury. Together, these findings suggest coordinated transcriptional regulation governing antioxidative, antiapoptotic, and anti-inflammatory responses. Historically, IRI has been framed primarily as an innate immune process driven by reactive oxygen species, complement activation, and leukocyte recruitment. The present study reframes this paradigm toward intracellular programming. Rather than merely responding to inflammatory damage, hepatocytes actively determine injury severity through signaling networks regulating mitochondrial stability, oxidative defense, and transcriptional resilience. This interpretation aligns with emerging evidence indicating that early parenchymal stress responses initiated during ischemia generate danger signals that subsequently drive innate immune amplification during reperfusion.6 The translational implications are compelling. If validated in larger cohorts, BMK1 expression could serve as a biomarker of graft resilience, potentially informing organ acceptance decisions or perioperative management strategies.7 However, several questions remain before clinical application. The absence of association with 30- or 90-d complications suggests that BMK1 currently reflects early biochemical recovery rather than durable outcomes. Longitudinal studies linking BMK1 signaling to graft survival, biliary complications, or chronic dysfunction will be essential. Therapeutic manipulation of MAPK signaling also warrants caution. BMK1 participates in oncogenic and endothelial signaling pathways, raising concerns regarding off-target effects or tumor promotion in chronically immunosuppressed recipients.8 Although mechanistically elegant, several limitations deserve consideration. The human analysis is retrospective and single center, introducing potential selection bias and confounding clinical variables.3 Donor characteristics and warm ischemia times may also influence observed associations.9 Additionally, murine partial warm ischemia models do not fully replicate the complexity of clinical transplantation. Although the ITCH-large tumor suppressor kinase 1 mechanism is compelling, further studies are required to define precisely the mechanisms through which BMK1 regulates ITCH activity and downstream transcriptional responses. These gaps represent important opportunities for future investigation. The broader significance of this work lies in its conceptual implications. Transplantation is entering an era increasingly defined by cellular engineering, machine perfusion preservation, and molecular risk stratification informed by emerging multiomics approaches to IRI.10 Pathways such as BMK1 may ultimately be leveraged during ex situ organ preservation to precondition grafts toward repair rather than injury. The integration of MAPK and Hippo signaling highlights the growing recognition that regenerative signaling and stress adaptation are tightly coupled determinants of graft survival. Therapies enhancing adaptive cellular programs, rather than suppressing inflammation, may represent the next frontier in graft protection. In summary, Liu et al4 present a mechanistically rich study identifying BMK1 as a critical regulator of hepatocellular resilience during IRI. By linking BMK1 to YAP-KLF4 transcriptional cooperation across human and experimental systems, this work reinforces the evolving view that transplant outcomes are shaped not only by immunologic compatibility but also by intrinsic cellular programming. Although further validation is required, these findings position cellular resilience as an emerging determinant of graft survival.